PRGS and LOAR reported strong results. Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at ...

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

This year, researchers Megan Shen, PhD, and Mary L. “Nora” Disis, MD, of Fred Hutch Cancer Center and UW Medicine ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

A woman underwent surgery to remove what she had been told was ovarian cancer. She was overjoyed when her results came back ...

Carly Allen was diagnosed with Stage 2 ovarian cancer. Doctors believe they were able to remove all the cancer before it ...

Ovarian cancer affects over 22,000 women annually in the U.S., yet only 20% of cases are caught early. With no reliable ...

Ovarian cancer, historically challenging to diagnose due to vague early symptoms, often reaches advanced stages before ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

Brain Pathway Links Inflammation to Loss of Motivation, Energy in Advanced Cancer Apr. 10, 2025 — Researchers identified a direct connection between cancer-related inflammation and the loss of ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).